Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 2 months (60 to 74 days) inclusive on the day of inclusion~* Born at full term pregnancy (³36 weeks) with a birth weight ≥ 2.5 kg~* Informed consent form signed by the parent(s) or other legal representative~* Able to attend all scheduled visits and to comply with all trial procedures~Exclusion Criteria :~* Participation in another clinical trial in the 4 weeks preceding the trial inclusion~* Planned participation in another clinical trial during the present trial period~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy~* Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion~* Blood or blood-derived products received in the past~* Any vaccination performed or planned in the 4 weeks preceding the first trial visit (except BCG and Hepatitis B, which can not be given within 8 days before the first study visit)~* Vaccination planned in the 4 weeks following any trial vaccination (except BCG and Hepatitis B, which can not be given within 8 days before or after the study vaccine(s) administration)~* History of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b infection (confirmed either clinically, serologically or microbiologically)~* Clinical or serological evidence of systemic illness including Hepatitis B, Hepatitis C and/or HIV infection~* Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis diseases or Haemophilus influenzae type b infection with the trial vaccine or another vaccine~* Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination~* History of/current seizures~* Febrile illness (axillary temperature ≥ 37.1°C) or acute illness on the day of inclusion

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 74 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): DTacP IPV// PRP\~T combined vaccine at 2, 3 and 4 months of age, and a booster dose at 18-20 months of age.
- 2 (Type: EXPERIMENTAL): DTacP-IPV// PRP\~T combined vaccine at 3, 4 and 5 months of age and a booster dose at 18-20 months of age.
- 3 (Type: ACTIVE_COMPARATOR): Control vaccines at 3, 4 and 5 months of age and a booster dose at 18-20 months of age

Based on this trial design, predict the completion outcome and termination type (if applicable).